Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796260 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT03796260 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 14 participants.
The verdict
NCT03796260, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study aims to investigate the relative bioavailability, safety, and tolerability of entrectinib capsule formulations F1 and F06 under fed conditions in healthy adult male and female participants.
Interventions
- DRUG Entrectinib Test Formulation (F1)
- DRUG Entrectinib Reference Formulation (F06)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-01-09 |
| Est. Completion | 2019-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03796260
The ClinicalTrials.gov registry entry for NCT03796260 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Entrectinib Test Formulation (F1) is the first listed.
NCT03796260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03796260 about?
NCT03796260 is a clinical study titled "A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants". This study aims to investigate the relative bioavailability, safety, and tolerability of entrectinib capsule formulations F1 and F06 under fed conditions in healthy adult male and female participants.
What is the current status of trial NCT03796260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-01-09. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT03796260?
The interventions under investigation include: Entrectinib Test Formulation (F1) (DRUG), Entrectinib Reference Formulation (F06) (DRUG).
Who is sponsoring clinical trial NCT03796260?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.